Genmab — November 2015
-
No, that’s fair. Percentage increase I’m comfortable. My question was regarding the number of events. So it's like less studies is for 550 patient, so the number of events you’re looking for is, is it like almost half of the patients would have been that or 300 patients.
Jan van de Winkel - President & Chief Executive Officer
It’s likely a smaller set seven of patients, but I cannot give you the exact number. -
Det er jo ikke et helt nemt regnestykke uanset hvad, da patienterne også indrulles løbende og vel færdigindrullet i Pollux midt på året. 40% af patienterne er gået i progression efter 16 måneder for Elo/Len/Dex armen. Så i dette tilfælde ville vi måske få interimdata sent i 2016. Mit eget løse bud vil måske være sommeren 2016, men det er jo lidt svært at komme helt nær
-
Ja..Lad os endelig få så mange spørgsmåind som muligt. Gerne allerede i dag og i morgen.
-
Også gerne til Zealand Pharma Q&A på fredag. Her må gerne gøres reklame på EI for begivenheden. Der sidder nogle hardcore fan, som sikkert også har gode spørgsmål at stille.
http://www.proinvestor.com/index.php?p=q-and-a&groupid=63 -
Fint med et lille ryk op i slutauktionen.
-
Det kan du have ret i Bulder.
-
-
Det er sgu god humor Bulder.
-
PS: Det mest sete klip i dag på Børsen Play er om teknisk analyse på Genmab. http://play.borsen.dk/social/563f6a79725ed7540a0c6988
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind